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ABSTRACT 
Context: Terminalia arjuna is a medicinal plant used as a cardiotonic in Ayurveda. The presence of 
potent antioxidant constituents results in improvement in endothelial dysfunction seen in coronary 
artery disease.  
Aim: To evaluate the cardiovascular and pharmacodynamic effects of single and multiple doses of 
Terminalia arjuna in healthy human male subjects.  
Settings and Design: Randomized, double blind, placebo-controlled dose ranging study.  
Methods and Material: After approval from the institutional ethics committee, written informed 
consent was taken from subjects. Eligible subjects were allocated to the single and multiple dose 
groups, with six subjects in each group. The active treatment (Terminalia arjuna crude powder 
capsules of 500 mg, 1000 mg, 1500 mg & 2000 mg single dose and 1500 mg multiple dose) and 
placebo capsules were administered in 2:1 ratio in all the study groups. Vital parameters and 
pharmacodynamic assessment of cardiac profiling were performed using cold pressor test (CPT), 
tilt table and platelet aggregation tests.  
Statistical analysis used: The data was presented as mean ±SD. No statistical tests were applied as 
the sample size was less (n=6 in each group).  
Results: During CPT, Terminalia arjuna attenuated the rise in SBP, DBP and pulse rate in all the 
treatment groups compared to baseline. The CPT induced arterial stiffness was counteracted by 
treatment with 1500 mg & 2000 mg single dose and 1500 mg multiple doses of Terminalia arjuna. 
Cardiac output was increased with 1500 mg multiple dose at 600 tilt (Day 1) and at 450 & 600 phases 
of the tilt (Day 11). Platelet aggregation was markedly inhibited in 1500 mg multiple doses at Day 
11. 
Conclusions: Treatment with single (1500 mg & 2000 mg) and multiple doses (1500 mg for 10 
days) of Terminalia arjuna produced remarkable changes in the cardiovascular profile. Further 
studies in larger number of subjects and in patients with cardiovascular diseases are needed to 
confirm these effects. 
KEYWORDS: Terminalia arjuna, Cardiotonic, Cold pressor test. 
INTRODUCTION
Terminalia arjuna (TA) is a medicinal plant 
used as a cardiotonic in Ayurveda. [1] It’s stem bark 
possesses glycosides, large quantities of flavonoids, 
tannins and minerals. Flavonoids have been detected to 
exert antioxidant, anti-inflammatory and lipid lowering 
effects while glycosides are cardiotonic. The presence 
of potent antioxidant constituents results in 
improvement in endothelial dysfunction seen in 
coronary artery disease and thus making Terminalia 
arjuna unique amongst currently used medicinal 
plants. [2] 
The stem bark of Terminalia arjuna possesses 
diuretic, inotropic, and chronotropic properties.[3] 
Experimental studies of the aqueous extract of 
Terminalia arjuna have demonstrated dose-dependent 
decrease in blood pressure [3], an increase in the 
coronary flow [4], bradycardia [5], and an increase in the 
force of contraction of cardiac muscle. The inotropic 
effect is considered to be mediated through the high 
concentration of Ca++ present in the plant. [6] 
Further, studies have shown that the dried 
bark augments endogenous antioxidant compounds 
and thus prevent oxidative stress associated with 
ischemic–reperfusion injury of the heart [7] thereby 
protecting the myocardium against ischemic damage. [8] 
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Clinical studies involving stable angina 
patients evaluated the anti-ischemic effect of bark 
powder of Terminalia arjuna given as 500 mg three 
times a day. There was a significant fall in the mean 
anginal frequency, systolic blood pressure (SBP) and 
serum cholesterol levels with improvement in ECG 
changes.[9] 
However, there are no dose response studies 
evaluating the effects of Terminalia arjuna in healthy 
human subjects. Hence, this study was undertaken to 
evaluate the cardiovascular and pharmacodynamic 
effects of single and multiple doses of Terminalia 
arjuna in healthy human male subjects. 
METHODOLOGY 
The study was designed as a randomized, 
double blind, placebo-controlled dose ranging study to 
evaluate the effect of single dose (500 mg, 1000 mg, 
1500 mg & 2000 mg) and multiple doses (500 mg three 
times a day for 10 days) of Terminalia arjuna (TA), 
conducted in the Department of Clinical Pharmacology 
and Therapeutics, NIMS, Hyderabad. The study was 
approved by the institutional ethics committee and all 
subjects gave written informed consent prior to 
participation in the study.  
Healthy male subjects were screened 
according to the eligibility criteria of the study protocol 
and all vital parameters and lab safety parameters 
were performed one week prior to study initiation.  
The eligible subjects were allocated to the 
single and multiple dose study groups, with six subjects 
in each group. The active treatment (Terminalia arjuna 
crude powder capsules of 500 mg, 1000 mg, 1500 mg & 
2000 mg single dose and 1500 mg multiple dose) and 
placebo capsules were administered in 2:1 ratio in all 
the study groups, with 4 subjects receiving Terminalia 
arjuna and 2 subjects receiving placebo, as per prior 
randomization schedule. All the single doses were 
given on the day of study and multiple doses of 1500 
mg were given as 1 capsule of 500 mg three times a day 
for 10 days.  
 The baseline measurements of vital 
parameters and pharmacodynamic assessment of 
cardiac profiling of subjects in all the groups were 
performed after an overnight fast, using non-invasive 
methods. The various cardiac profiling parameters that 
were assessed include - Brachial-Ankle Pulse Wave 
Velocity (baPWV) (cm/s) and Ankle-Brachial Index 
(ABI-Colin), Reflection Index (RI%) (Micromedical 
Pulse Tracer Gallingham, Kent, UK), Aortic 
Augmentation Pressure (AP) (mmHg), Pulse Pressure 
(PP) (mmHg), Aortic Augmentation Index (AIx) (%) 
and Sub Endocardial Viability Ratio (SEVR) (%) 
(Sphygmocor®) before and after cold pressor test 
(CPT). Blood pressure and pulse rate were taken 
before, during and after CPT. Then, tilt table test was 
performed and blood pressure, basal Impedance 
(ohms), cardiac output (L/min), cardiac index (L/min/ 
m2), stroke volume (ml/beat), stroke volume index 
(ml/beat/m2), systemic vascular resistance (dyne.sec/ 
cm5), systemic vascular resistance index (dyne.sec/ 
cm5/m2), left ventricular ejection time (ms), pulse rate 
(bpm), velocity index (/1000sec) and central velocity 
pressure (mmHg) were measured at 0°, 45°, 60°and 
again at baseline 0° tilt using L&T Nivomon monitor. 
Pretreatment blood samples were drawn for 
assessment of safety parameters.  
Single Dose Group 
In all the single dose groups, all procedures 
were repeated 3 hours post drug, as done at baseline 
and all the parameters were recorded. The subject’s 
vital parameters were recorded before and at hourly 
intervals up to 6 hrs and then at 8, 12 and 24 hrs post 
treatment. The lab safety parameters were measured at 
24 hours post administration of study medication. Any 
adverse drug reaction (ADR) reported was recorded in 
case report form. Subjects were discharged from the 
clinical research unit after all vital parameters were 
found to be normal 24 hours post treatment.  
Multiple Dose Group 
The dose of 1500 mg was chosen for multiple 
dose study as 1500 mg is the recommended dose for 
Terminalia arjuna and has been evaluated in clinical 
studies earlier.[10] The dose was administered as one 
capsule of Terminalia arjuna 500 mg, three times a day. 
The initial dose was administered at the study site and 
all the procedures were conducted 3 hours post drug, 
as described above for single dose study. The subjects 
were asked to continue study medication for next 10 
days. At day 11, after an overnight fast, baseline 
measurements of vital parameters were recorded and 
all the procedures done on day 1 were repeated. Any 
adverse drug reaction (ADR) reported was recorded in 
the case report form.  
 
Figure: Terminalia arjuna and placebo capsules 
RESULTS 
Six volunteers each were enrolled and 
randomized in the study groups. All subjects completed 
the study uneventfully. The demographic 
characteristics of the study groups were homogenous 
in nature, as shown in Table 1. 
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Table1: Demographic Data 
 Total No. Age (yrs) Weight (Kg) BMI (Kg/m2) 
TA 500 mg Group 
TA Group 4 31.00 ± 2.16 63.53 ±9.34 23.44 ± 2.58 
Placebo 2 29.00±4.24  66.30±23.62 22.81±6.50 
TA 1000 mg Group 
TA Group 4 35.25±8.77 61.05±6.22 22.56±3.38 
Placebo 2 29.50±0.71 62.25±0.21 22.63±0.81 
TA 1500 mg Group 
TA Group 4 30.00±1.83 63.50±2.08 23.04±0.65 
Placebo 2 30.50±3.53 74.00±12.73 24.34±2.62 
TA 2000 mg Group 
TA Group 4 32.0±2.16 64.50±4.2 24.28±1.24 
Placebo 2 31.0±0.01 65.15±7.7 25.16±3.41 
TA 1500 mg Multiple Dose Group 
TA Group 4 33.75±2.50 66.75±1.70 24.20±1.37 
Placebo 2 31.50±0.70 63.50±0.70 23.55±0.63 
Effect of treatments on vital parameters with Cold Pressor test 
In all the study groups, cold pressor test (CPT) increased systolic, diastolic blood pressure (SBP, DBP) and 
pulse rate (PR) at 30 sec during the test from baseline, whereas after 1 min and 10 min of CPT, SBP, DBP & PR were 
within normal limits. At 3hrs post treatment with Terminalia arjuna 500 mg single dose, there were increases in 
SBP, DBP & PR at 30 sec during CPT which were however much lower than that compared to pre-treatment values. 
Similar effects were seen with 1000 mg, 1500 mg & 2000 mg single dose and 1500 mg multiple dose treatments. In 
the placebo group, after 3hrs of treatment, cold pressor test did not produce any remarkable changes in the vital 
parameters from baseline to during 30sec, after 1min and 10min of CPT.  
Table 2A - Effect of CPT on pharmacodynamic parameters at baseline – Single dose group 
 baPWV 
(cm/s) 
ABI Reflection 
Index (RI%) 
AP(mmHg) PP(mmHg) AIX (%) SEVR (%) 
TA 500 mg Group 
TA Before 
CPT 
1153±69.1 1.03±0.02 79.48±6.73 8.00±1.15 33.25±4.92 131.8±2.06 183.8±4.03 
TA After CPT 1158±55.45 1.06±0.02 78.23±6.81 9.75±2.75 34.50±9.25 140.5±3.69 197.3±2.21 
Placebo 
Before CPT 
1173±3.53 1.09±0.05 76.65±4.73 5.00±1.41 31.00±2.82 121.0±9.89 177.0±7.07 
Placebo 
After CPT 
1185±21.21 1.09±0.00 72.65±0.91 11.00±2.82 35.00±11.31 145.0±5.65 191.0±5.65 
TA 1000 mg Group 
TA Before 
CPT 
1186±31.46 1.08±0.05 83.90±2.81 5.75±0.95 27.25±0.95 126.0±1.41 165.0±9.55 
TA After CPT 1218±20.21 1.09±0.06 80.95±2.89 7.75±0.95 29.50±1.29 138.3±3.59 182.0±10.30 
Placebo 
Before CPT 
1163±53.03 1.09±0.003 78.95±1.90 7.50±2.12 35.00±1.41 131.0±4.24 167.5±4.95 
Placebo 
After CPT 
1175±0.0 1.04±0.017 74.30±5.23 8.5±2.12 33.50±2.12 143.0±4.24 184.5±3.53 
TA 1500 mg Group 
TA Before 
CPT 
1125±45.64 0.975±0.02 79.65±2.63 7.00±2.94 33.00±2.944 21±6.97 180.3±22.97 
TA After CPT 1223±117 1.074±0.04 82.05±3.21 11.50±2.38 30.75±0.9574 37±7.39 173.8±31.45 
Placebo 
Before CPT 
1213±17.68 1.04±0.046 79.80±2.121 2.00±1.414 29.50±2.121 7±4.243 117.0±21.21 
Placebo 
After CPT 
1350±35.36 1.00±0.042 81.15±1.63 6.00±2.828 33.50±2.121 17.±7.071 136.5±12.02 
TA 2000 mg Group 
TA Before 
CPT 
1169±8.48 1.08±0.03 65.98±4.62 8.00±0.81 23.25±0.95 131.5±3.69 155.5±7.93 
TA After CPT 1225±0.01 1.11±0.03 71.80±4.58 12.50±1.29 30.25±2.21 144.0±3.74 148.3±7.50 
Placebo 
Before CPT 
1188.0±53.03 1.09±0.91 68.45±1.62 8.0±0.01 25.00±1.41 136.5±6.36 171.0±9.89 
Placebo 
After CPT 
1288.0±17.68 1.12±0.00 73.50±2.12 11.50±0.70 33.50±0.70 141.5±3.53 163.5±3.53 
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Table 2B - Effect of CPT on pharmacodynamic parameters at baseline – Multiple dose group 
 baPWV 
(cm/s) 
ABI Reflection 
Index (RI%) 
AP(mmHg) PP(mmHg) AIX (%) SEVR (%) 
TA 1500 mg Multiple Dose Group: Day 1 
TA Before CPT 1119.0±79.2 1.09±0.02 71.73±1.17 9.50±3.10 23.25±2.63 133.8±6.55 153.0±10.86 
TA After CPT 1238.0±0.01 1.12±0.01 75.05±1.60 13.75±1.70 28.50±2.08 146.0±1.82 149.5±9.88 
Placebo  
Before CPT 
1138±17.68 1.13±0.0 73.15±4.03 9.50±3.53 22.0±1.41 132.5±4.95 151.5±3.53 
Placebo After 
CPT 
1300±35.36 1.09±0.0 78.65±1.90 11.50±3.53 26.0±2.82 143.0±1.41 148.0±5.65 
TA 1500 mg Multiple Dose Group: Day 11 
TA Before CPT 1113±17.68 1.13±0.0 70.55±4.47 7.50±1.73 22.25±0.95 130.8±4.99 142.8±4.11 
TA After CPT 1057±26.16 1.14±0.20 68.23±5.51 5.00±0.81 19.50±1.29 121.3±2.5 151.3±9.5 
Placebo  
Before CPT 
1150 ±106.1 1.13±0.0 68.50±0.70 7.50±0.70 23.0±1.41 130.5±2.12 137.5±2.12 
Placebo After 
CPT 
1238 ±123.7 1.15±0.0 73.00± 1.41 12.50±0.70 30.00±2.82 140.0±1.41 133.5±6.36 
 The cold pressor test produced arterial stiffness at baseline and the same is evidenced by an increase in baPWV, 
RI, AP, PP and AIx and in all groups also as a decrease in values of SEVR in 1500 mg, 2000 mg single dose and 1500 
mg multiple dose and placebo groups. 
Effect of Treatments on Pharmacodynamic parameters during Cold Pressor test 
Table 3A - Effect of treatments on pharmacodynamic parameters during CPT – Single dose group 
 baPWV 
(cm/s) 
ABI Reflection 
Index (RI%) 
AP(mmHg) PP(mmHg) AIX (%) SEVR (%) 
TA 500 mg Group 
TA Before CPT 1178±35.24 1.06±0.02 80.00±3.74 6.75±1.25 33.50±3.78 125.8±3.50 177.5±6.80 
TA After CPT 1159±88.73 1.06±0.04 79.13±5.15 8.25±1.70 31.75±2.63 136.0±6.92 195.3±10.81 
Placebo Before 
CPT 
1175±0.00 1.07±0.00 78.3±6.08 6.50±0.71 30.5±3.54 124±12.0 175±7.78 
Placebo After 
CPT 
1203±3.53 1.11±0.00 75.7±3.32 9.00±0.00 31.0±1.41 141±0.70 194±22.6 
TA 1000 mg Group 
TA Before CPT 1216±30.92 1.15±0.08 85.08±2.46 7.00±0.81 27.0±0.81 132.5±4.04 174.8±8.34 
TA After CPT 1188±30.69 1.13±0.02 80.98±4.61 9.75±1.89 31.75±3.40 144.5±5.44 201.3±12.45 
Placebo Before 
CPT 
1178±53.03 1.093±0.01 80.60±2.82 6.50±0.70 30.0±1.41 114.5±4.95 151.0±9.89 
Placebo After 
CPT 
1208±24.75 1.098±0.01 78.80±0.70 7.50±0.70 35.0±1.41 128.0±1.41 176.5±2.12 
TA 1500 mg Group 
TA Before CPT 1263±59.51 1.11±0.03 80.15±6.16 6.50±3.87 34.00±6.976 18.25±7.455 152.8±31.60 
TA After CPT 1204±48.88 0.97±0.02 78.15±6.03 5.75±2.87 27.75±5.188 20.00±5.416 167.3±45.01 
Placebo Before 
CPT 
1225±0.01 1.05±0.03 80.50±2.121 1.5±0.7 6.0±2.828 28.0±0.0 121.0±29.7 
Placebo After 
CPT 
1338±53.03 1.07±0.06 80.80±0.28 3.50±2.121 12.0±8.485 28.50±0.71 144.0±22.63 
TA 2000 mg Group 
TA Before CPT 1200±35.36 1.13±0.02 67.40±2.96 7.75±0.95 23.25±1.89 136.0±11.78 155.8±6.60 
TA After CPT 1144±43.84 1.10±0.02 62.50±2.38 6 ±0.81 19 ±1.15 130.8±12.63 162.5±10.75 
Placebo Before 
CPT 
1163±53.03 1.06±0.01 70.10±4.95 7.50±0.70 24.50±2.12 132.5±0.7 161.5±17.68 
Placebo After 
CPT 
1250±35.36 1.11±0.01 73.45±4.03 12 ±1.41 30.50±0.7 140.5±2.12 148.0±0.01 
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Table 3B - Effect of treatments on pharmacodynamic parameters during CPT – Multiple dose group 
 baPWV 
(cm/s) 
ABI Reflection 
Index (RI%) 
AP(mmHg) PP(mmHg) AIX (%) SEVR (%) 
TA 1500 mg Multiple Dose Group Day 1 
TA Before CPT 1207±9.92 1.13±0.01 72.55±1.18 6.75±0.95 24.25±2.63 124.5±5.68 144.3±0.86 
TA After CPT 1150±35.36 1.15±0.03 69.80±2.46 5.25±1.78 21.50±3.41 120.5±2.08 161.0±6.68 
Placebo 
Before CPT 
1113±17.68 1.11±0.03 71.50±0.70 7.0±0.0 22.50±0.70 129.5±2.12 143.5±0.70 
Placebo After 
CPT 
1225±70.71 1.08±0.01 79.0±1.41 11.50±2.12 27.50±3.53 140.0±2.82 134.5±17.68 
TA 1500 mg Multiple Dose Group Day 11 
TA Before CPT 1107±61.52 1.13±0.0 71.65±1.98 7.75±1.70 20.25±1.50 127.5±8.22 133.3±10.69 
TA After CPT 1032±44.55 1.15±0.0 67.9±2.45 5.50±1.29 18.25±1.25 119.5±7.55 146.3±4.03 
Placebo 
Before CPT 
1150±35.36  
1.19±0.00 
70.8±2.54 8.50±0.70 20.50±2.12 131.0±4.24 150.0±2.82 
Placebo After 
CPT 
1213±88.39 1.14±0.01 74.95±0.91 12.50±0.70 28.50±0.70 145.5±4.95 147.5±0.70 
 Treatment with Terminalia arjuna decreased baPWV in all the treatment groups. However the changes in other 
pharmacodynamic parameters recorded during cold pressor test were not found to be remarkable. The CPT 
induced arterial stiffness was counteracted by treatment with Terminalia arjuna and there was decrease in baPWV, 
RI, AP, PP, AIx and increase in SEVR in 1500 mg, 2000 mg single dose and 1500 mg multiple dose groups both at 
Day 1 & Day 11. There were no remarkable changes in the placebo group.  
Effect of Treatments on Tilt Table Test on Various Pharmacodynamic parameters  
Tilt table test per se did not produce any remarkable change in SBP, DBP, PR and cardiac output at different 
degrees of tilt in any of the study groups. Treatment with Terminalia arjuna 1500 mg & 2000 mg single doses 
produced a mild increase in cardiac output during 450 & 600 phases of the tilt. Terminalia arjuna 1500 mg multiple 
dose increased cardiac output at 600 tilt (Day 1) and at 450 & 600 phases of the tilt (Day 11).  
Table 4: Effect of Treatments on Platelet aggregation test 
  % Platelet Aggregation (ADP) 
Pretreatment Post Treatment % Inhibition 
TA 500 mg Group 
T.arjuna 75.00±2.85 78.88±2.89 Nil 
Placebo 76.8±0.35 78.0±0.1 Nil 
TA 1000 mg Group 
T.arjuna 75.75±2.53 78.38±2.05 Nil 
Placebo 76.50±1.14 78.75±1.77 Nil 
TA 1500 mg Group 
T.arjuna 74.0±3.65 78.75±2.63 Nil 
Placebo 77.25±3.889 80.75±2.475 Nil 
TA 2000 mg Group 
T.arjuna 65.63±7.01 63.38±9.12 4.81±3.95 
Placebo 69.25±8.13 71.65±9.40 Nil 
TA 1500 mg Multiple Dose Group Day 1 
T.arjuna 70.50±2.12 73.38±2.13 Nil 
Placebo 67.75±1.76 69.75±2.47 Nil 
TA 1500 mg Multiple Dose Group Day 11 
T.arjuna 69.25±2.90 58.0±3.24 16.28±1.60 
Placebo 70.25±3.18 69.75±7.42 1.80±2.54 
Significant inhibition in platelet aggregation 
was seen with Terminalia arjuna 2000 mg single dose 
and Terminalia arjuna 1500 mg multiple dose at day 
11. Placebo treatment did not produce any change in 
the platelet aggregation test. 
Adverse Events – All subjects tolerated both 
treatments and procedures well. No subjects developed 
any adverse drug reaction. Study was completed 
uneventful. There were no remarkable changes in any 
of the hematological, biochemical safety lab parameters 
with either treatment. 
DISCUSSION 
This was a placebo-controlled, phase I dose 
ranging study evaluating the safety and efficacy of 
single doses of Terminalia arjuna 500 mg, 1000 mg, 
1500 mg & 2000 mg single dose and multiple dose of 
Pingali Usharani et al. Cardiovascular and Pharmacodynamic Effects of Terminalia arjuna  
 Available online at : http://ijapr.in  6 
Terminalia arjuna 1500 mg (500 mg three times a day 
for 10 days) on cardiovascular profile in healthy human 
male volunteers.  
The stem bark of Terminalia arjuna has been 
used for the treatment of various cardiovascular 
diseases in preclinical studies to demonstrate 
cardioprotective properties including positive 
inotropic, hypolipdemic, coronary vasodilatory and 
antioxidant effects. The biologically active compounds 
in the stem bark include triterpinoids, tannins, 
flavonoids and minerals. [11] 
In our study, cold pressor test (CPT) was 
performed to induce arterial stiffness which manifested 
as an increase in systolic and diastolic blood pressure 
and pulse rate. Treatment with Terminalia arjuna 
resulted in lower increments in SBP, DBP & PR, at 30 
sec during CPT compared to pretreatment CPT 
increments of the same parameters, thus attenuating 
the cardiovascular effect of CPT & protecting against 
arterial stiffness. Within the treatments, Terminalia 
arjuna 1500 mg multiple dose produced lower 
increments at Day 11 compared to any of the single 
doses of Terminalia arjuna. This effect of Terminalia 
arjuna may be ascribed to it’s cardioprotective 
properties of vasodilation and anti-oxidant effects. Also 
few experimental studies have demonstrated it’s anti-
hypertensive activity. [12] This has been attributed to 
certain tannins and glycosides that strengthen heart 
muscles, relieve stress and have specific antioxidant 
properties congenial for the cardiovascular 
system.[13,14] 
Further, CPT–induced arterial stiffness was 
also evaluated with changes in pharmacodynamic 
parameters before and after CPT. Treatment with 
Terminalia arjuna 1500 mg for 10 days counteracted 
the CPT induced arterial stiffness by decreasing 
baPWV, RI, AP, PP, AIx and increase in SEVR compared 
to baseline. This effect was seen with both single and 
multiple doses of Terminalia arjuna, with the effect 
being more prominent in multiple dose group. This 
indicates that multiple dose administration of 
Terminalia arjuna protects against the cardiovascular 
effects induced by cold pressor test.  
The role  of  vascular endothelium has been 
studied in relation to arterial stiffness and it was 
demonstrated that an intact and functional vascular 
endothelium is essential to maintain vascular tone thus 
countering any arterial stiffness. [15] By virtue of it’s 
anti-oxidant activity, Terminalia arjuna promotes the 
function of intact vascular endothelium.  
The cardiac function was also assessed with tilt 
table test. Treatment with both single and multiple 
doses of Terminalia arjuna did not alter the vital 
parameters except for a mild increase in cardiac output 
at 45 and 60 degree tilt, which was comparable in both 
the groups. This effect may be due to the cardiotonic 
activity of Terminalia arjuna manifesting as positive 
inotropy and positive lusitropy secondary to 
enhancement in calcium handling of myocardial 
sarcoplasmic reticulum.[16]  
The effect of Terminalia arjuna on platelet 
aggregation was evaluated using agonists- ADP & 
Collagen. Inhibition of platelet aggregation was seen 
with Terminalia arjuna 2000 mg single dose and 1500 
mg multiple dose at Day 11. However, this effect was 
much higher with the multiple dose treatment 
suggesting a dose-dependent inhibition of platelet 
aggregation by Terminalia arjuna. The anti-platelet 
aggregatory effect of Terminalia arjuna may be due to 
it’s property of desensitizing platelets to the agonist by 
competing with platelet receptor or by interfering with 
signal transduction.[17]  
Both the treatments were safe and well 
tolerated and no adverse effects were reported in 
either of the treatment groups. 
CONCLUSION 
There were no significant changes in any of the 
pharmacodynamic parameters tested with single dose 
of 500 mg & 1000 mg Terminalia arjuna. However, 
treatment with single doses of 1500 mg & 2000 mg and 
multiple doses of 1500 mg for 10 days of Terminalia 
arjuna produced remarkable changes in the 
cardiovascular profile. The active treatments showed 
mild decrease in pharmacodynamic parameters such as 
baPWV, AIx, AP, PP, ABI and reflection index on cold 
pressor test & a mild increase in cardiac output at 45o 
and 60o of tilt compared to baseline. Marked reduction 
in platelet aggregation was recorded in the 1500 mg 
multiple dose treatment group. All the treatments were 
safe, well tolerated and no adverse events were 
reported. Further studies in larger number of subjects 
and in patients with cardiovascular diseases are 
needed to confirm these effects of Terminalia arjuna on 
cardiovascular profile. 
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